Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year.
GlaxoSmithKline's COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive E
Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirna
Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit m
The UK Competition and Markets Authority has ruled that several drugmakers worked together to raise the NHS price of widely-used nausea drug prochlorperazine, fining them £35 million ($47.5
Roche has warned that revenue growth will come under pressure in the coming year as sales of its COVID-19 testing kits start to slow, exposing the impact of biosimilar competition to some o